Seres Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Seres Therapeutics, Inc. (MCRB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 54.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-12
- Seres Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 54.10%, a 5310.00% increase from fiscal 2024.
- Seres Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 1.00%, a 25.00% increase from fiscal 2023.
- Seres Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.80%.
- Seres Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was -0.70%, a 275.00% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 54.10% 10-K · filed 2026-03-12 | |
| 2024-12-31 | 1.00% 10-K · filed 2026-03-12 | -1.00% 10-K · filed 2025-03-13 |
| 2023-12-31 | 0.80% 10-K · filed 2026-03-12 | -1.40% 10-K · filed 2024-03-05 |
| 2022-12-31 | -0.70% 10-K · filed 2025-03-13 | -0.60% 10-K · filed 2023-03-07 |
| 2021-12-31 | 0.40% 10-K · filed 2024-03-05 | |
| 2020-12-31 | 5.80% 10-K · filed 2023-03-07 | |
| 2019-12-31 | 1.70% 10-K · filed 2022-03-01 | |
| 2018-12-31 | -2.00% 10-K · filed 2021-03-02 | |
| 2017-12-31 | -1.20% 10-K · filed 2020-03-02 | |
| 2016-12-31 | 6.30% 10-K · filed 2019-03-06 | |
| 2015-12-31 | -4.10% 10-K · filed 2018-03-08 | 4.10% 10-K · filed 2016-03-14 |
| 2014-12-31 | -2.30% 10-K · filed 2017-03-16 | 2.30% 10-K · filed 2016-03-14 |
| 2013-12-31 | 1.20% 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |